Follow-up and subsequent treatment after standard therapy of gastrointestinal stromal tumor
LI Guo-li
HE Qi
Abstract：Gastrointestinal stromal tumor (GIST) is considered to have malignant potential and has a high risk of recurrence and metastasis. GIST patients need a systematic follow-up after standard treatment. Imatinib is the first choice for metastatic and unresectable GIST. Targeted therapy before surgery is a main treatment,and the majority criteria for evaluating treatment is the tumor can or cannot be surgically removed after the treatment, which is not equal to the therapeutic evaluation. Following surgical resection of GIST, adjuvant treatment with imatinib ameliorates the outcomes. Higher dose of imatinib, regorafenib and pazopanib could be used for patients who fail the standard therapy.
Keywords：gastrointestinal stromal tumorfollow-uprecur-rencemetastasis
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 415-418 )